Diabetic kidney disease: from physiology to therapeutics
- PMID: 24907306
- PMCID: PMC4198010
- DOI: 10.1113/jphysiol.2014.272328
Diabetic kidney disease: from physiology to therapeutics
Abstract
Diabetic kidney disease (DKD) defines the functional, structural and clinical abnormalities of the kidneys that are caused by diabetes. This complication has become the single most frequent cause of end-stage renal disease. The pathophysiology of DKD comprises the interaction of both genetic and environmental determinants that trigger a complex network of pathophysiological events, which leads to the damage of the glomerular filtration barrier, a highly specialized structure formed by the fenestrated endothelium, the glomerular basement membrane and the epithelial podocytes, that permits a highly selective ultrafiltration of the blood plasma. DKD evolves gradually over years through five progressive stages. Briefly they are: reversible glomerular hyperfiltration, normal glomerular filtration and normoalbuminuria, normal glomerular filtration and microalbuminuria, macroalbuminuria, and renal failure. Approximately 20-40% of diabetic patients develop microalbuminuria within 10-15 years of the diagnosis of diabetes, and about 80-90% of those with microalbuminuria progress to more advanced stages. Thus, after 15-20 years, macroalbuminuria occurs approximately in 20-40% of patients, and around half of them will present renal insufficiency within 5 years. The screening and early diagnosis of DKD is based on the measurement of urinary albumin excretion and the detection of microalbuminuria, the first clinical sign of DKD. The management of DKD is based on the general recommendations in the treatment of patients with diabetes, including optimal glycaemic and blood pressure control, adequate lipid management and abolishing smoking, in addition to the lowering of albuminuria.
© 2014 The Authors. The Journal of Physiology © 2014 The Physiological Society.
Figures
Similar articles
-
Normoalbuminuric diabetic kidney disease.Front Med. 2017 Sep;11(3):310-318. doi: 10.1007/s11684-017-0542-7. Epub 2017 Jul 18. Front Med. 2017. PMID: 28721497 Review.
-
Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster.Nephrology (Carlton). 2015 Mar;20(3):216-23. doi: 10.1111/nep.12379. Nephrology (Carlton). 2015. PMID: 25495003
-
Long-term intra-individual variability of albuminuria in type 2 diabetes mellitus: implications for categorization of albumin excretion rate.BMC Nephrol. 2017 Dec 6;18(1):355. doi: 10.1186/s12882-017-0767-3. BMC Nephrol. 2017. PMID: 29207965 Free PMC article.
-
Sexual dimorphism in the progression of type 2 diabetic kidney disease in T2DN rats.Physiol Genomics. 2021 Jun 1;53(6):223-234. doi: 10.1152/physiolgenomics.00009.2021. Epub 2021 Apr 19. Physiol Genomics. 2021. PMID: 33870721 Free PMC article.
-
[Non-Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review].Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 Nov 20;54(6):1074-1079. doi: 10.12182/20231160102. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 38162079 Free PMC article. Review. Chinese.
Cited by
-
Transient receptor potential vanilloid 4 channels as therapeutic targets in diabetes and diabetes-related complications.J Diabetes Investig. 2020 Jul;11(4):757-769. doi: 10.1111/jdi.13244. Epub 2020 Apr 16. J Diabetes Investig. 2020. PMID: 32129549 Free PMC article. Review.
-
Cytoprotective Effect of Liposomal Puerarin on High Glucose-Induced Injury in Rat Mesangial Cells.Antioxidants (Basel). 2021 Jul 24;10(8):1177. doi: 10.3390/antiox10081177. Antioxidants (Basel). 2021. PMID: 34439425 Free PMC article.
-
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.Am J Kidney Dis. 2021 Apr;77(4):481-489. doi: 10.1053/j.ajkd.2020.09.009. Epub 2020 Oct 29. Am J Kidney Dis. 2021. PMID: 33130235 Free PMC article. Clinical Trial.
-
Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!Rev Physiol Biochem Pharmacol. 2021;179:31-71. doi: 10.1007/112_2020_50. Rev Physiol Biochem Pharmacol. 2021. PMID: 32979084 Review.
-
Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction: Insights into Pathophysiology and Recent Advances.Cardiorenal Med. 2025;15(1):41-60. doi: 10.1159/000542633. Epub 2025 Jan 3. Cardiorenal Med. 2025. PMID: 39756385 Free PMC article. Review.
References
-
- Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR UKPDS Group. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64) Kidney Int. 2003;63:225–232. - PubMed
-
- American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care. 2014;37(Suppl. 1):S14–S80. - PubMed
-
- Andress DL, Coll B, Pritchett Y, Brennan J, Molitich M, Kohan DE. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD) Life Sci. 2012;91:739–742. - PubMed
-
- Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602–613. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical